Last Price
1.29
Today's Change
-0.005 (0.38%)
Day's Change
1.26 - 1.34
Trading Volume
909,656
Market Cap
238 Million
Shares Outstanding
184 Million
Avg Volume
1,048,366
Avg Price (50 Days)
1.25
Avg Price (200 Days)
1.10
PE Ratio
-1.44
EPS
-0.90
Earnings Announcement
05-Nov-2024
Previous Close
1.30
Open
1.26
Day's Range
1.26 - 1.345
Year Range
0.41 - 1.93
Trading Volume
909,864
1 Day Change
-0.38%
5 Day Change
13.60%
1 Month Change
4.44%
3 Month Change
10.68%
6 Month Change
36.32%
Ytd Change
117.72%
1 Year Change
127.23%
3 Year Change
-92.85%
5 Year Change
-92.53%
10 Year Change
-89.43%
Max Change
-65.47%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.